drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
An autologous BCMA-directed chimeric antigen receptor (CAR) T-cell therapy in which patient T cells are collected, engineered ex vivo to express a BCMA-targeted CAR, expanded, and reinfused to mediate antigen-dependent T-cell activation, proliferation, cytokine release, and cytotoxic killing of myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are collected and genetically engineered ex vivo to express a chimeric antigen receptor targeting BCMA, then expanded and reinfused. Upon BCMA binding on myeloma cells, CAR signaling (CD3ΞΆ with costimulation) drives T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, with potential persistence for ongoing tumor control.
drug_name
CG-105-12
nct_id_drug_ref
NCT06999031